Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 1;9(9):MR000065.
doi: 10.1002/14651858.MR000065.pub2.

Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis

Pauline Meskell  1 , Linda M Biesty  2 , Maura Dowling  2 , Kevin Roche  3 , Elaine Meehan  4 , Claire Glenton  5 , Declan Devane  2 , Sasha Shepperd  6 , Andrew Booth  7 , Rebecca Cox  8 , Xin Hui S Chan  9 , Catherine Houghton  2
Affiliations
Review

Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis

Pauline Meskell et al. Cochrane Database Syst Rev. .

Abstract

Background: The World Health Organization declared the COVID-19 pandemic on 11 March 2020. Vaccine development and deployment were swiftly prioritised as a method to manage and control disease spread. The development of an effective vaccine relies on people's participation in randomised trials. Recruitment to vaccine trials is particularly challenging as it involves healthy volunteers who may have concerns around the potential risks and benefits associated with rapidly developed vaccines.

Objectives: To explore the factors that influence a person's decision to participate in a vaccine trial in the context of a pandemic or epidemic.

Search methods: We used standard, extensive Cochrane search methods. The latest search date was June 2021.

Selection criteria: We included qualitative studies and mixed-methods studies with an identifiable qualitative component. We included studies that explored the perspectives of adults aged 18 years or older who were invited to take part in vaccine trials in the context of a pandemic or epidemic.

Data collection and analysis: We assessed the title, abstracts and full texts identified by the search. We used a sampling frame to identify data-rich studies that represented a range of diseases and geographical spread. We used QSR NVivo to manage extracted data. We assessed methodological limitations using an adapted version of the Critical Skills Appraisal Programme (CASP) tool for qualitative studies. We used the 'best-fit framework approach' to analyse and synthesise the evidence from our included studies. We then used the Confidence in the Evidence from Reviews of Qualitative research (GRADE-CERQual) assessment to assess our confidence in each finding and develop implications for practice.

Main results: We included 34 studies in our review. Most studies related to HIV vaccine trials. The other studies related to Ebola virus, tuberculosis, Zika virus and COVID-19. We developed 20 key findings, under three broad themes (with seven subthemes), that described the factors that people consider when deciding whether to take part in a vaccine trial for a pandemic or epidemic disease. Our GRADE-CERQual confidence was high in nine of the key findings, moderate in 10 key findings and low in one key finding. The main reason for downgrading review findings were concerns regarding the relevance and adequacy of the underlying data. As a result of the over-representation of HIV studies, our GRADE-CERQual assessment of some findings was downgraded in terms of relevance because the views described may not reflect those of people regarding vaccine trials for other pandemic or epidemic diseases. Adequacy relates to the degree of richness and quantity of data supporting a review finding. Moderate concerns about adequacy resulted in a downgrading of some review findings. Some factors were considered to be under the control of the trial team. These included how trial information was communicated and the inclusion of people in the community to help with trial information dissemination. Aspects of trial design were also considered under control of the trial team and included convenience of participation, provision of financial incentives and access to additional support services for those taking part in the trial. Other factors influencing people's decision to take part could be personal, from family, friends or wider society. From a personal perceptive, people had concerns about vaccine side effects, vaccine efficacy and possible impact on their daily lives (carer responsibilities, work, etc.). People were also influenced by their families, and the impact participation may have on relationships. The fear of stigma from society influenced the decision to take part. Also, from a societal perspective, the level of trust in governments' involvement in research and trial may influence a person's decision. Finally, the perceived rewards, both personal and societal, were influencing factors on the decision to participate. Personal rewards included access to a vaccine, improved health and improved disease knowledge, and a return to normality in the context of a pandemic or epidemic. Potential societal rewards included helping the community and contributing to science, often motivated by the memories of family and friends who had died from the disease.

Authors' conclusions: This review identifies many of the factors that influence a person's decision to take part in a vaccine trial, and these reflect findings from reviews that examine trials more broadly. However, we also recognise some factors that become more important in connection with a vaccine trial in the context of a pandemic or epidemic. These factors include the potential stigma of taking part, the possible adverse effects of a vaccine, the added motivation for helping society, the role of community leaders in trial dissemination, and the level of trust placed in governments and companies developing vaccines. These specific influences need to be considered by trial teams when designing, and communicating about, vaccine trials in the context of a pandemic or epidemic.

PubMed Disclaimer

Conflict of interest statement

PM: none.

LB: none.

MD: none.

KR: none.

EM: none.

CG: is a Cochrane editor but was not involved in the editorial process of this review.

DD: Cochrane Pregnancy and Childbirth Group Editor but was not involved in the editorial process of this review.

SS: is a Cochrane editor but was not involved in the editorial process of this review.

AB: is a Cochrane editor but was not involved in the editorial process of this review.

RC: none.

XHC: none.

CH: none.

Figures

1
1
2
2
Figure 2 Decision Train
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.MR000065

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Adewoyin 2013 {published data only}
    1. Adewoyin B. Perceived Barriers to Participation in HIV Vaccine Trials among Eligible Men Who Have Sex with Men. Master of Public Health 2013.
Andrasik 2014 {published data only}
    1. Andrasik MP, Yoon R, Mooney J, Broder G, Bolton M, Votto T, et al, team Hvtn study, Network Niaid HIV Vaccine Trials. Exploring barriers and facilitators to participation of male-to-female transgender persons in preventive HIV vaccine clinical trials. Prevention Science 2014;15(3):268-76. - PMC - PubMed
Brooks 2007 {published data only}
    1. Brooks RA, Newman PA, Duan N, Ortiz DJ. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care 2007;19(1):52-8. - PubMed
Chakrapani 2012 {published data only}
    1. Chakrapani V, Newman PA, Singhal N, Jerajani J, Shunmugam M. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach. PLOS One 2012;7(12):e51080. - PMC - PubMed
Chin 2016 {published data only}
    1. Chin LJ, Berenson JA, Klitzman RL. Typologies of Altruistic and Financial Motivations for Research Participation. Journal of Empirical Research on Human Research Ethics 2016;11(4):299-310. - PMC - PubMed
Craig 2018 {published data only}
    1. Craig SR, Lahey T, Dixit A, Fordham von Reyn C. Altruism, scepticism, and collective decision-making in foreign-born U.S. residents in a tuberculosis vaccine trial. BMC Public Health 2018;18(1):535. - PMC - PubMed
David 2021 {published data only}
    1. David PM, Mathiot B, Thiongane O, Graham JE. Under consent: participation of people with HIV in an Ebola vaccine trial in Canada. BMC Medical Ethics 2021;22(1):42. - PMC - PubMed
Gobat 2018 {published data only}
    1. Gobat NH, Gal M, Butler CC, Webb SA, Francis NA, Stanton H, et al. Talking to the people that really matter about their participation in pandemic clinical research: a qualitative study in four European countries. Health Expectations 2018;21(1):387-95. - PMC - PubMed
Grantz 2019 {published data only}
    1. Grantz KH, Claudot P, Kambala M, Kouyate M, Soumah A, Boum Y, et al. Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea. Vaccine 2019;37(48):7165-70. - PubMed
Jaffe 2020 {published data only}
    1. Jaffe E, Lyerly AD, Goldfarb IT. Pregnant women's perceptions of risks and benefits when considering participation in vaccine trials. Vaccine 2020;38(44):6922-9. - PMC - PubMed
Jalloh 2019 {published data only}
    1. Jalloh MF, Jalloh MB, Albert A, Wolff B, Callis A, Ramakrishnan A, et al. Perceptions and acceptability of an experimental Ebola vaccine among health care workers, frontline staff, and the general public during the 2014–2015 Ebola outbreak in Sierra Leone. Vaccine 2019;37(11):1495-502. - PMC - PubMed
Koniak‐Griffin 2007 {published data only}
    1. Koniak-Griffin D, Nyamathi A, Tallen L, Gonzalez-Figueroa E, Dominick E. Breaking the silence: what homeless 18- to 24-year-olds say about HIV vaccine trials. Journal of Health Care for the Poor and Underserved 2007;18(3):687-98. - PubMed
Lesch 2006 {published data only}
    1. Lesch A, Kafaar Z, Kagee A, Swartz L. Community members' perceptions of enablers and inhibitors to participation in HIV vaccine trials. South African Journal of Psychology 2006;36(4):734-61.
Mbunda 2018 {published data only}
    1. Mbunda T. Count in the Young People: HIV Vaccine Trial Participation in Tanzania. openarchive.ki.se/xmlui/handle/10616/46489 (accessed prior to 1 June 2023).
Moutsiakis 2007 {published data only}
    1. Moutsiakis DL, Chin PN. Why blacks do not take part in HIV vaccine trials. Journal of the National Medical Association 2007;99(3):254-7. - PMC - PubMed
Newman 2006 {published data only}
    1. Newman PA, Duan N, Roberts KJ, Seiden D, Rudy ET, Swendeman D, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. Journal of Acquired Immune Deficiency Syndromes 2006;41(2):210-7. - PubMed
Newman 2008a {published data only}
    1. Newman PA, Duan N, Kakinami L, Roberts K. What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine 2008;26(20):2528-36. - PMC - PubMed
Newman 2008b {published data only}
    1. Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 2008;26(8):1091-7. - PubMed
Newman 2011a {published data only}
    1. Newman PA, Yim S, Daley A, Walisser R, Halpenny R, Cunningham W, et al. "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination. Vaccine 2011;29(3):451-8. - PMC - PubMed
Newman 2011b {published data only}
    1. Newman PA, Logie C, James L, Charles T, Maxwell J, Salam K, et al. "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown. American Journal of Public Health 2011;101(9):1749-58. - PMC - PubMed
Newman 2015 {published data only}
    1. Newman PA, Rubincam C, Slack C, Essack Z, Chakrapani V, Chuang DM, et al. Towards a science of community stakeholder engagement in biomedical HIV prevention trials: an embedded four-country case study. PLOS One 2015;10(8):e0135937. - PMC - PubMed
Nguyen 2021 {published data only}
    1. Nguyen D, Arnaert A, Pringle J, Ponzoni N, Kouyaté S, Fansia N, et al. Nurses' experiences of their decision-making process when participating in clinical trials during the 2014–2016 West African Ebola crisis. Public Health Nursing 2021;38(1):40-6. - PubMed
Nyamathi 2004 {published data only}
    1. Nyamathi A, Koniak-Griffin D, Tallen L, Gonzalez-Figueroa E, Levson L, Mosley Y, et al. Use of community-based participatory research in preparing low income and homeless minority populations for future HIV vaccines. Journal of Interprofessional Care 2004;18(4):369-80. - PubMed
Nyblade 2011 {published data only}
    1. Nyblade L, Singh S, Ashburn K, Brady L, Olenja J. "Once I begin to participate, people will run away from me": understanding stigma as a barrier to HIV vaccine research participation in Kenya. Vaccine 2011;29(48):8924-8. - PubMed
Olin 2006 {published data only}
    1. Olin J, Kokolamami J, Lepira FB, Mwandagalirwa K, Mupenda B, Ndongala ML, et al. Community preparedness for HIV vaccine trials in the Democratic Republic of Congo. Cult Health Sex 2006;8(6):529-44. - PubMed
Slomka 2008 {published data only}
    1. Slomka J, Ratliff EA, McCurdy SA, Timpson S, Williams ML. Decisions to participate in research: views of underserved minority drug users with or at risk for HIV. AIDS Care 2008;20(10):1224-32. - PMC - PubMed
Strauss 2001 {published data only}
    1. Kegeles SM, Johnson MO, Strauss RP, Ralston B, Hays RB, Metzger DS, et al. How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out. AIDS Education and Prevention 2006;18(6):560-72. - PubMed
    1. Strauss RP, Sengupta S, Kegeles S, McLellan E, Metzger D, Eyre S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. Journal of Acquired Immune Deficiency Syndromes 2001;26(1):63-71. - PubMed
Tarimo 2010 {published data only}
    1. Tarimo EA, Thorson A, Kohi TW, Mwami J, Bakari M, Sandstrom E, et al. Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania. BMC Public Health 2010;10:292. - PMC - PubMed
Tarimo 2011 {published data only}
    1. Tarimo EA, Thorson A, Kohi TW, Bakari M, Mhalu F, Kulane A. Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania. PLOS One 2011;6(2):e14619. - PMC - PubMed
Tarimo 2019 {published data only}
    1. Tarimo EA, Ambikile J, Munseri P, Bakari M. Perception of potential harm and benefits of HIV vaccine trial participation: a qualitative study from urban Tanzania. PLOS One 2019;14(11):e0224831. - PMC - PubMed
Tengbeh 2018 {published data only}
    1. Tengbeh AF, Enria L, Smout E, Mooney T, Callaghan M, Ishola D, et al. "We are the heroes because we are ready to die for this country": participants' decision-making and grounded ethics in an Ebola vaccine clinical trial. Social Science & Medicine 2018;203:35-42. - PubMed
Toledo 2014 {published data only}
    1. Toledo L, McLellan-Lemal E, Arreola S, Campbell C, Sutton M. African-American and Hispanic perceptions of HIV vaccine clinical research: a qualitative study. American Journal of Health Promotion 2014;29(2):e82-90. - PubMed
Voytek 2011 {published data only}
    1. Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection. Vaccine 2011;29(36):6130-5. - PMC - PubMed
Wentzell 2021 {published data only}
    1. Wentzell E, Racila AM. The social experience of participation in a COVID-19 vaccine trial: subjects' motivations, others' concerns, and insights for vaccine promotion. Vaccine 2021;39(17):2445-51. - PMC - PubMed

References to studies excluded from this review

Cattapan 2019 {published data only}
    1. Cattapan A, Browne K, Halperin DM, Di Castri A, Fullsack P, Graham J, et al. Motivation for participating in phase 1 vaccine trials: comparison of an influenza and an Ebola randomized controlled trial. Vaccine 2019;37(2):289-95. - PubMed
Doshi 2017 {published data only}
    1. Doshi M, Avery L, Kaddu RP, Gichuhi M, Gakii G, du Plessis E, et al. Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials. BMC Public Health 2017;17(1):469. - PMC - PubMed
Ekezie 2021 {published data only}
    1. Ekezie W, Czyznikowska BM, Rohit S, Harrison J, Miah N, Campbell-Morris P, et al. The views of ethnic minority and vulnerable communities towards participation in COVID-19 vaccine trials. Journal of Public Health 2021;43(2):e258-60. - PMC - PubMed
Enria 2016 {published data only}
    1. Enria L, Lees S, Smout E, Mooney T, Tengbeh AF, Leigh B, et al. Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone. BMC Public Health 2016;16:10. - PMC - PubMed
Hays 1999 {published data only}
    1. Hays RB, Kegeles SM. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1999;20(2):164-71. - PubMed
Liamputtong 2015 {published data only}
    1. Liamputtong P, Haritavorn N, Kiatying-Angsulee N. Participating in HIV clinical trials: reasons and experiences among women living with HIV in Thailand. Journal of HIV/AIDS & Social Services 2015;14(2):239-56.
Lindegger 2007 {published data only}
    1. Lindegger G, Quayle M, Ndlovu M. Local knowledge and experiences of vaccination: implications for HIV-preventive vaccine trials in South Africa. Health Education & Behavior 2007;34(1):108-23. - PubMed
Nyamathi 2007 {published data only}
    1. Nyamathi AM, Suhadev M, Swaminathan S, Fahey JL. Perceptions of a community sample about participation in future HIV vaccine trials in south India. AIDS and Behavior 2007;11(4):619-27. - PubMed
Nyaoke 2017 {published data only}
    1. Nyaoke BA, Mutua GN, Sajabi R, Nyasani D, Mureithi MW, Anzala OA. Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya. PLOS One 2017;12(9):e0183788. - PMC - PubMed
Ryan 1995 {published data only}
    1. Ryan L. 'Going public' and 'watching sick people' – the clinic setting as a factor in the experiences of gay men participating in AIDS clinical trials. AIDS Care 1995;7(2):147-58. - PubMed

Additional references

Ames 2017
    1. Ames HM, Glenton C, Lewin S. Parents' and informal caregivers' views and experiences of communication about routine childhood vaccination: a synthesis of qualitative evidence. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No: CD011787. [DOI: 10.1002/14651858.CD011787.pub2] - DOI - PMC - PubMed
Ames 2019
    1. Ames H, Glenton C, Lewin S. Purposive sampling in a qualitative evidence synthesis: a worked example from a synthesis on parental perceptions of vaccination communication. BMC Medical Research Methodology 2019;19(1):26. [DOI: 10.1186/s12874-019-0665-4] - DOI - PMC - PubMed
Atuire 2022
    1. Atuire CA, Salas S, Wright K Ambe J, deVries J. COVID-19 vaccine trials with children: ethics pointers. BMJ Global Health 2022;7:e007466. [DOI: 10.1136/bmjgh-2021-007466] - DOI - PMC - PubMed
Bagcchi 2020
    1. Bagcchi S. Stigma during the COVID-19 pandemic. Lancet Infectious Diseases 2020;20(7):782. - PMC - PubMed
Bidad 2016
    1. Bidad N, MacDonald L, Winters ZE, Edwards SJ, Emson M, Griffin CL, et al. How informed is declared altruism in clinical trials? A qualitative interview study of patient decision-making about the QUEST trials (Quality of Life after Mastectomy and Breast Reconstruction). Trials 2016;17(1):431. - PMC - PubMed
Blehar 2013
    1. Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Womens Health Issues 2013;23:e39-e45. - PMC - PubMed
Booth 2015
    1. Booth A, Carroll C. How to build up the actionable knowledge base: the role of 'best fit' framework synthesis for studies of improvement in healthcare. BMJ Quality & Safety 2015;24:700-8. [DOI: 10.1136/bmjqs-2014-003642] - DOI - PMC - PubMed
Borobia 2021
    1. Borobia AM, García-García I, Díaz-García L, Rodríguez-Mariblanca A, Martínez de Soto L, Monserrat Villatoro J, et al. Health care workers' reasons for choosing between two different COVID-19 prophylaxis trials in an acute pandemic context: single-center questionnaire study. Journal of Medical Internet Research 2021;23(2):e23441. [DOI: 10.2196/23441] - DOI - PMC - PubMed
Bower 2007
    1. Bower P, Wilson S, Mathers N. Short report: how often do UK primary care trials face recruitment delays? Family Practice 2007;24(6):601-3. [DOI: 10.1093/fampra/cmm051] - DOI - PubMed
Brooks 2020
    1. Brooks SK, Webster RK, Smith LE. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 2020;395(10227):912-20. [DOI: 10.1016/S0140-6736(20)30460-8] - DOI - PMC - PubMed
Canvin 2006
    1. Canvin K, Jacoby A. Duty, desire or indifference? A qualitative study of patient decisions about recruitment to an epilepsy treatment trial. Trials 2006;7(1):32. - PMC - PubMed
Carlsen 2016
    1. Carlsen B, Glenton C. The swine flu vaccine, public attitudes, and researcher interpretations: a systematic review of qualitative research. BMC Health Service Research 2016;16:203. [DOI: 10.1186/s12913-016-1466-7] - DOI - PMC - PubMed
Carroll 2013
    1. Carroll C, Booth A, Leaviss J, Rick J. "Best fit" framework synthesis: refining the method. BMC Medical Research Methodology 2013;13:37. [DOI: 10.1186/1471-2288-13-37] - DOI - PMC - PubMed
CASP 2018
    1. Critical Appraisal Skills Programme. CASP Qualitative Checklist. casp-uk.net/casp-tools-checklists/ (accessed 1 June 2023).
Cochrane (EPOC)
    1. Cochrane Effective Practice and Organisation of Care (EPOC). Qualitative Evidence Syntheses guidance on when to sample and how to develop a purposive sampling frame. epoc.cochrane.org/resources/epoc-resources-review-authors (accessed after 2 December 2021).
Covidence [Computer program]
    1. Covidence. Version accessed after 2 December 2021. Melbourne, Australia: Veritas Health Innovation, 2021. Available at covidence.org.
Craig 2020
    1. Craig AM, Hughes BL, Swamy GK. COVID-19 vaccines in pregnancy. American Journal of Obstetrics & Gynecology 2020;3(2):100295. [DOI: 10.1016/j.ajogmf.2021.100324] - DOI - PMC - PubMed
Darzi 2021
    1. Darzi A, Goddard A, Henderson K, Mahajan R, Marx C, Mortensen N, et al. Increasing recruitment into COVID-19 trials. BMJ 2021;372:n235. [DOI: 10.1136/bmj.n235] - DOI - PubMed
Davis 2020
    1. Davis J, Ferreira D, Denholm JT, Tong S. Clinical trials for the prevention and treatment of COVID-19: current state of play. Medical Journal of Australia 2020;213:86-93. [DOI: 10.5694/mja2.50673] - DOI - PMC - PubMed
Detoc 2017
    1. Detoc M, Gagneux-Brunon A, Lucht F, Botelho-Nevers E. Barriers and motivations to volunteers' participation in preventive vaccine trials: a systematic review. Expert Review of Vaccines 2017;16(5):467-77. [DOI: 10.1080/14760584.2017.1297706] - DOI - PubMed
Detoc 2019
    1. Detoc M, Launay O, Dualé C, Mutter C, Le Huec J-C, Lenzi N, et al. Barriers and motivations for participation in preventive vaccine clinical trials: experience of 5 clinical research sites. Vaccine 2019;37:6633-9. [DOI: 10.1016/j.vaccine.2019.09.048] - DOI - PubMed
Dhalla 2013
    1. Dhalla S, Poole G. Barriers to participation in actual HIV vaccine trials. Current HIV Research 2103;11(3):238-45. [DOI: 10.2174/1570162x11311030009] - DOI - PubMed
Dyer 2020
    1. Dyer O. COVID-19: Eli Lilly pauses antibody trial for safety reasons. BMJ 2020;371:m3985. [DOI: 10.1136/bmj.m3985] - DOI - PubMed
Earnshaw 2020
    1. Earnshaw VA, Brousseau NM, Hill EC, Kalichman SC, Eaton LA, Fox AB. Anticipated stigma, stereotypes, and COVID-19 testing. Stigma and Health 2020;5(4):390-3. [DOI: 10.1037/sah0000255] - DOI
Fayter 2007
    1. Fayter D, McDaid C, Eastwood A. A systematic review highlights threats to validity in studies of barriers to cancer trial participation. Journal of Clinical Epidemiology 2007;60(10):990-1001. [DOI: 10.1016/j.jclinepi.2006.12.013] - DOI - PubMed
Finset 2020
    1. Finset A, Bosworth H, Butow P, Gulbrandsen P, Hulsman RL, Pieterse AH, et al. Effective health communication – a key factor in fighting the COVID-19 pandemic. Patient Education and Counseling 2020;103(5):873-6. [DOI: 10.1016/j. pec.2020.03.027] - PMC - PubMed
Flemming 2021
    1. Flemming K, Noyes J. Qualitative evidence synthesis: where are we at? International Journal of Qualitative Methods 2021;20:1. [DOI: 10.1177/1609406921993276] - DOI
Fletcher 2012
    1. Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open 2012;2(1):e000496. [DOI: 10.1136/bmjopen-2011-000496] - DOI - PMC - PubMed
Flores 2021
    1. Flores L, Frontera W, Andrasik M. Assessment of the inclusion of racial/ethnic minority, female and older individuals in vaccine trials. JAMA Network Open 2021;4(2):e2037640. [DOI: 10.10001/jamanetworkopen.2020.37640] - DOI - PMC - PubMed
Forcina 2018
    1. Forcina V, Vakeesan B, Paulo C, Mitchell L, Bell JA, Tam S, et al. Perceptions and attitudes toward clinical trials in adolescent and young adults with cancer: a systematic review. Adolescent Health, Medicine and Therapeutics 2018;9:87-94. [DOI: 10.2147/AHMT.S163121] - DOI - PMC - PubMed
Gill 2004
    1. Gill D, Ethics Working Group of the Confederation of European Specialists in Paediatrics. Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the ethics working group of the Confederation of European Specialists in Paediatrics (CESP). European Journal of Pediatrics 2004;163:53-7. - PubMed
Gill 2013
    1. Gill PS, Plumridge G, Khunti K, Greenfield S. Under-representation of minority ethnic groups in cardiovascular research: a semi-structured interview study. Family Practice 2013;30:233-41. - PubMed
Glenton 2022
    1. Glenton C, Bohren MA, Downe S, Paulsen EJ, Lewin S, on behalf of Effective Practice and Organisation of Care (EPOC). EPOC qualitative evidence synthesis: protocol and review template. Version 1.3. EPOC Resources for review authors. epoc.cochrane.org/epoc-specific-resources-review-authors (accessed prior to 5 June 2023). [WEBPAGE: epoc.cochrane.org/epoc-specific-resources-review-authors]
Glover 2015
    1. Glover M, Kira A, Johnston V, Walker N, Thomas D, Chang AB, et al. A systematic review of barriers and facilitators to participation in randomized controlled trials by Indigenous people from New Zealand, Australia, Canada and the United States. Global Health Promotion 2015;22(1):21-31. [DOI: 10.1177/1757975914528961] - DOI - PubMed
Gobat 2019
    1. Gobat N, Butler CC, Mollison J, Francis NA, Gal M, Harris V, et al. What the public think about participation in medical research during an influenza pandemic: an international cross-sectional survey. Public Health 2019;177:80-94. [DOI: 10.1016/j.puhe.2019.07.005] - DOI - PubMed
Gouglas 2018
    1. Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, et al. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Global Health 2018;6:e1386-96. [DOI: 10.1016/S2214-109X(18)30346-2] - DOI - PMC - PubMed
Gregersen 2019
    1. Gregersen TA, Birkelund R, Wolderslund M, Netsey-Afedo ML, Steffensen KD, Ammentorp J. What matters in clinical trial decision-making: a systematic review of interviews exploring cancer patients' experiences. Scandinavian Journal of Caring Sciences 2019;33(2):266-78. - PubMed
Hargreaves 2020
    1. Hargreaves JR, Logie CH. Lifting lockdown policies: a critical moment for COVID-19 stigma. Global Public Health 2020;15(12):1917-23. - PubMed
Harrington 2017
    1. Harrington L, Damme P, Vandermeulen C, Mali S. Recruitment barriers for prophylactic vaccine trials: a study in Belgium. Vaccine 2017;35(48 Pt B):6598-603. [PMID: ] - PubMed
Hodgson 2021
    1. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KR, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infectious Diseases 2021;21(2):e26-35. [DOI: 10.1016/S1473-3099(20)30773-8] - DOI - PMC - PubMed
Horsley 2011
    1. Horsley T, Dingwall O, Sampson M. Checking reference lists to find additional studies for systematic reviews. Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No: MR000026. [DOI: 10.1002/14651858.MR000026.pub2] - DOI - PMC - PubMed
Houghton 2017
    1. Houghton C, Murphy K, Meehan B, Thomas J, Brooker D, Casey D. From screening to synthesis: using nvivo to enhance transparency in qualitative evidence synthesis. Journal of Clinical Nursing 2017;26(5):873-81. [DOI: 10.1111/jocn.13443. PMID: 27324875] - PubMed
Houghton 2020
    1. Houghton C, Dowling M, Meskell P, Hunter A, Gardner H, Conway A, et al. Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews 2020, Issue 10. Art. No: MR000045. [DOI: 10.1002/14651858.MR000045.pub2] - DOI - PMC - PubMed
Huang 2022
    1. Huang L, Riggan KA, Ashby GB, Rivera-Chiauzzi EY, Allyse MA. Pregnant and postpartum patients' views of COVID-19 vaccination. Journal of Community Health 2022;47:871-8. [DOI: 10.1007/s10900-022-01118-z] - DOI - PMC - PubMed
Hughes‐Morley 2015
    1. Hughes-Morley A, Young B, Waheed W, Small N, Bower P. Factors affecting recruitment into depression trials: systematic review, meta-synthesis and conceptual framework. Journal of Affective Disorders 2015;172:274-90. - PubMed
Jaklevic 2020
    1. Jaklevic MC. Researchers strive to recruit hard-hit minorities into COVID-19 vaccine trials. JAMA 2020;324(9):826-8. [DOI: 10.1001/ jama.2020.11244a] - PubMed
Janiaud 2021
    1. Janiaud P, Axfors C, Ioannidis J, Hemkens L. Recruitment and results reporting of Covid-19 randomized clinical trials registered in the first 100 days of the pandemic. JAMA Network Open 2021;4(3):e210330. [DOI: 10.1001/jamanetworkopen.2021.0330] - DOI - PMC - PubMed
Joseph 2015
    1. Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. British Journal of Clinical Pharmacology 2015;79:357-69. [DOI: 10.1111/bcp.12305] - DOI - PMC - PubMed
Kalbaugh 2021
    1. Kalbaugh CA, Kalbaugh JM, McManus L, Fisher JA. Healthy volunteers in US phase I clinical trials: sociodemographic characteristics and participation over time. PLOS One 2021;16:e0256994. [DOI: 10.1371/journal.pone.0256994] - DOI - PMC - PubMed
Kaur 2012
    1. Kaur G, Smyth R, Williamson P. Developing a survey of barriers and facilitators to recruitment in randomized controlled trials. Trials 2012;13:218. - PMC - PubMed
Kiberd 2009
    1. Kiberd M, Cooper C, Slaunwhite J, Halperin B, Haase D, McNeil S. Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adults. Canadian Journal of Infectious Diseases and Medical Microbiology 2009;20:e124-9. [DOI: 10.1155/2009/156873] - DOI - PMC - PubMed
Kons 2022
    1. Kons K, Wood M, Peck L, Hershberger S, Kunselman A, Stetter C, et al. Exclusion of reproductive-aged women in Covid vaccination and clinical trials. Women Health Issues 2022;32(6):557-63. - PMC - PubMed
Langford 2020
    1. Langford AT. Health communication and decision making about vaccine clinical trials during a pandemic. Journal of Health Communication 2020;25(10):780-9. [DOI: 10.1080/10810730.2020.1864520] - DOI - PMC - PubMed
Larson 2016
    1. Larson H, Figueiredo A, Xiahong Z, Schulz W, Verger P, Johnston I, et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine 2016;12:295-301. [DOI: 10.1016/j.ebiom.2016.08.042] - DOI - PMC - PubMed
Ledford 2021
    1. Ledford H. Deaths from COVID 'incredibly rare' among children. Nature 2021;595:639.
Lewin 2018
    1. Lewin S, Booth A, Glenton C, Munthe-Kaas H, Rashidian A, Wainwright M, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. Implementation Science 2018;13(1):2. [DOI: 10.1186/s13012-017-0688-3] - DOI - PMC - PubMed
Li 2020
    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine 2020;382(13):1199-207. [DOI: 10.1056/NEJMoa2001316] - DOI - PMC - PubMed
Limkakeng 2013
    1. Limkakeng A, Phadtare A, Shah J, Vaghasia M, Wei DY, Shah A. Willingness to participate in clinical trials among patients of Chinese heritage: a meta-synthesis. PLOS One 2013;8(1):e51328. [DOI: 10.1371/journal.pone.0051328] - DOI - PMC - PubMed
Locock 2011
    1. Locock L, Smith L. Personal benefit, or benefiting others? Deciding whether to take part in clinical trials. Clinical Trials 2011;8(1):85-93. - PubMed
Lynch 2019
    1. Lynch HF, Joffe S, Thirumurthy H, Xie D, Largent EA. Association between financial incentives and participant deception about study eligibility. JAMA Network Open 2019;2:e187355-e. - PMC - PubMed
McCann 2010
    1. McCann SK, Campbell MK, Entwistle VA. Reasons for participating in randomised controlled trials: conditional altruism and considerations for self. Trials 2010;11(1):31. - PMC - PubMed
McCann 2013
    1. McCann S, Campbell M, Entwistle V. Recruitment to clinical trials: a meta-ethnographic synthesis of studies of reasons for participation. Journal of Health Services Research & Policy 2013;18(4):233-41. - PubMed
McDonald 2006
    1. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006;7:9. [DOI: 10.1186/1745-6215-7-9] - DOI - PMC - PubMed
Mills 2006
    1. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncology 2006;7(2):141-8. [DOI: 10.1016/S1470-2045(06)70576-9] - DOI - PubMed
Mintz 2021
    1. Mintz K, Jardas E, Shah S. Enrolling minors in COVID-19 vaccine trials. Pediatrics 2021;147:e2020040717. - PMC - PubMed
Mukumbang 2020
    1. Mukumbang FC, Ambe AN, Adebiyi BO. Unspoken inequality: how COVID-19 has exacerbated existing vulnerabilities of asylum-seekers, refugees, and undocumented migrants in South Africa. International Journal for Equity in Health 2020;19(1):141. - PMC - PubMed
Naidoo 2020
    1. Naidoo N, Nguyen VT, Ravaud P, Young B, Amiel P, Schante D, et al. The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence. BMC Medicine 2020;18(6):2-11. [DOI: 10.1186/s12916-019-1476-5] - DOI - PMC - PubMed
Nalubega 2015
    1. Nalubega S, Evans C. Participant views and experiences of participating in HIV research in sub-Saharan Africa: a qualitative systematic review. JBI Database of Systematic Reviews and Implementation Reports 2015;13(5):330-420. - PubMed
Nielsen 2019
    1. Nielsen ZE, Berthelsen CB. Cancer patients' perceptions of factors influencing their decisions on participation in clinical drug trials: a qualitative meta-synthesis. Journal of Clinical Nursing 2019;28(13-4):2443-61. - PubMed
Nievaard 2004
    1. Nievaard M, Vos R, Haes J, Levi M. Reasons why patients do or do not participate in clinical trials; a systemic review of the literature [Redenen voor patiënten om (niet) te participeren in klinische trials; een systematisch literatuuroverzicht]. Nederlands Tijdschrift voor Geneeskunde 2004;148(4):186-90. [PMID: ] - PubMed
O'Callaghan 2020
    1. O'Callaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 Vaccine at Warp Speed. JAMA 2020;324(5):437-8. [DOI: 10.1001/jama.2020.12190] - DOI - PubMed
Okoro 2021
    1. Okoro O, Kennedy J, Simmons G. Exploring the scope and dimensions of vaccine hesitancy and resistance to enhance COVID-19 vaccination in black communities. Journal of Racial and Ethnic Health Disparities 2021;6:2119-30. [DOI: 10.1007/s40615-021-01150-0] - DOI - PMC - PubMed
Olsen 2020
    1. Olsen L, DePalma L, Evans JH. Self-interested and altruistic motivations in volunteering for clinical trials: a more complex relationship. Journal of Empirical Research on Human Research Ethics 2020;15(5):443-51. - PubMed
Petkova 2020
    1. Petkova E, Antman EM, Troxel AB. Pooling data from individual clinical trials in the COVID-19 era. JAMA 2020;324(6):543-5. [DOI: 10.1001/jama.2020.13042] - DOI - PubMed
Prescott 1999
    1. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technology Assessment 1999;3(20):iii-139. [DOI: 10.1016/s0895-4356(99)00141-9] - DOI - PubMed
Public Health England 2020
    1. Public Health England. Disparities in the risk and outcomes of COVID-19. Public Health England 2020;London (UK).
Quinn 2019
    1. Quinn SC, Jamison AM, An J, Hancock GR, Freimuth VS. Measuring vaccine hesitancy, confidence, trust and flu vaccine uptake: results of a national survey of White and African American adults. Vaccine 2019;37(9):1168-73. [DOI: 10.1016/j.vaccine.2019.01.033] - DOI - PubMed
Raisi‐Estabragh 2020
    1. Raisi-Estabragh Z, McCracken C, Bethell MS. Greater risk of severe COVID-19 in Black, Asian and minority ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25 (OH)-vitamin D status: study of 1326 cases from the UK biobank. Journal of Public Health 2020;42(3):451-60. - PMC - PubMed
Razai 2021
    1. Razai MS, Kankam HK, Majeed A, Esmail A, Williams DR. Mitigating ethnic disparities in COVID-19 and beyond. BMJ 2021;372:m4921. [DOI: 10.1136/bmj.m4921 pmid: 33446485] - PubMed
Robertson 2021
    1. Robertson E, Reeve K, Niedzwiedz C, Moore J, Blake M, Green M, et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behavior and Immunity 2021;94:41-50. [DOI: 10.1016/j.bbi.2021.03.008] - DOI - PMC - PubMed
Robinson 2021
    1. Robinson E, Jones A, Daly M. International estimates of intended uptake and refusal of COVID-19 vaccines: a rapid systematic review and meta-analysis of large nationally representative samples. Vaccine 2021;39(15):2024-34. [DOI: 10.1016/j.vaccine.2021.02.005] - DOI - PMC - PubMed
Sethi 2020
    1. Sethi BA, Sethi A, Ali S, Aamir HS. Impact of Coronavirus disease (COVID-19) pandemic on health professionals. Pakistan Journal of Medical Science 2020;36(COVID19-S4):S6-S11. [DOI: 10.12669/pjms.36.COVID19-S4.2779] - DOI - PMC - PubMed
Sheridan 2020
    1. Sheridan R, Martin KJ, Hudson J, Parker A, Bower P, Knapp P. Why do patients take part in research? An overview of systematic reviews of psychosocial barriers and facilitators. Trials 2020;21(1):259. - PMC - PubMed
Smith 2011
    1. Smith R. Stigma communication and health. In: Thompson T, Parrott R, Nussbaum J, editors(s). Handbook of Health Communication. New York (NY): Taylor & Francis, 2011:455-68.
Smith 2020
    1. Smith DD, Pippen JL, Adesomo AA, Rood KM, Landon MB, Costantine MM. Exclusion of pregnant women from clinical trials during the coronavirus disease 2019 pandemic: a review of international registries. American Journal of Perinatology 2020;37:792-9. - PMC - PubMed
Sopory 2022
    1. Sopory P, Novak JM, Noyes JP. Quarantine acceptance and adherence: qualitative evidence synthesis and conceptual framework. Journal of Public Health (Berlin) 2022;30:2091-101. [DOI: 10.1007/s10389-021-01544-8] - DOI - PMC - PubMed
Sotgiu 2020
    1. Sotgiu G, Dobler CC. Social stigma in the time of coronavirus disease 2019. European Respiratory Journal 2020;56(2):2002461. - PMC - PubMed
Stangl 2019
    1. Stangl AL, Earnshaw VA, Logie CH, Brakel W, Simbayi L, Barré I, et al. The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Medicine 2019;17(1):31. - PMC - PubMed
Stoeckel 2022
    1. Stoeckel F, Carter C, Lyons B, Reifler J. The politics of vaccine hesitancy in Europe. European Journal of Public Health 2022;32(4):636-42. - PMC - PubMed
Sully 2013
    1. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials 2013;14:166. [DOI: 10.1186/1745-6215-14-166] - DOI - PMC - PubMed
Suri 2011
    1. Suri H. Purposeful sampling in qualitative research synthesis. Qualitative Research Journal 2011;11(2):63-75.
Swan 2009
    1. Swan J, Robertson M, Evans S. Managing clinical research in the UK: summary of finding; 2009. qmro.qmul.ac.uk/xmlui/bitstream/handle/123456789/1014/Robertson%20managi... (accessed prior to 1 June 2023).
Taylor 2021
    1. Taylor MM, Kobeissi L, Kim C, Amin A, Thorson AE, Bellare NB, Broutet N. Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. Lancet Global Health 2021;9:e366-71. - PMC - PubMed
Treweek 2018
    1. Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sullivan F, et al. Strategies to improve recruitment to randomised trials. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No: MR000013. [DOI: 10.1002/14651858.MR000013.pub6] - DOI - PMC - PubMed
Treweek 2020
    1. Treweek S, Forouhi NG, Narayan KM, Khunti K. COVID-19 and ethnicity: who will research results apply to? Lancet 2020;395(10242):1955-7. - PMC - PubMed
Villa 2020
    1. Villa S, Jaramillo E, Mangioni D, Bandera A, Gori A, Raviglione MC. Stigma at the time of the COVID-19 pandemic. Clinical Microbiology and Infection 2020;26(11):1450-2. - PMC - PubMed
Wagner 2020
    1. Wagner M, Rosumeck S, Küffmeier C, Döring K, Euler U. A validation study revealed differences in design and performance of MEDLINE search filters for qualitative research. Journal of Clinical Epidemiology 2020;120:17-24. [DOI: 10.1016/j.jclinepi.2019.12.008] - DOI - PubMed
Walters 2017
    1. Walters SJ, Bonacho dos Anjos Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques RM, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open 2017;7:e015276. [DOI: 10.1136/bmjopen-2016-015276] - DOI - PMC - PubMed
Wang 2020
    1. Wang C, Pan R, Wan X. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. International Journal of Environmental Research and Public Health 2020;17(5):1729. [DOI: 10.3390/ijerph17051729] - DOI - PMC - PubMed
Wang 2021
    1. Wang Z, Chen G, Liu X, Liu C, Song Q, Wang J. The motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research. European Journal of Clinical Pharmacology 2021;77:557-68. - PubMed
WHO 2014
    1. World Health Organization (WHO). Safety of Immunization during pregnancy. A review of the evidence. Global Advisory Committee on Vaccine Safety. www.who.int/publications/i/item/WHO-HIS-2014.07 (accessed 15 February 2023).
WHO 2020a
    1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 – 11 March 2020; 2020. www.who.int/director-general/speeches/detail/who-director-general-s-open... (accessed prior to 1 June 2023).
WHO 2020b
    1. World Health Organization. Social stigma associated with COVID-19: a guide to preventing and addressing social stigma. www.who.int/publications/m/item/a-guide-to-preventing-and-addressing-soc... (accessed 2 June 2023). [WHO: www.who.int/publications/m/item/a-guide-to-preventing-and-addressing-soc...
Wilson 2021
    1. Wilson B, Wright K, Taylor R, Higgs E. Beyond recruitment: good participatory practice enhances the impact of research in a pandemic. Nature Medicine 2021;27:367-71. [DOI: 10.1038/s41591-021-01271-3] - DOI - PubMed
Woodall 2010
    1. Woodall A, Morgan C, Sloan C, Howard L. Barriers to participation in mental health research: are there specific gender, ethnicity and age related barriers? BMC Psychiatry 2010;10(1):103. [DOI: 10.1186/1471-244X-10-103] - DOI - PMC - PubMed
Yao 2020
    1. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry 2020;7(4):e21. - PMC - PubMed

References to other published versions of this review

Meskell 2022
    1. Meskell P, Biesty LM, Dowling M, Meehan E, Glenton C, Devane D, et al. Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews 2022, Issue 1. Art. No: MR000065. [DOI: 10.1002/14651858.MR000065] - DOI - PMC - PubMed

Publication types